A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia

PURPOSE: Gemtuzumab ozogamicin (GO) is indicated for treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). The QT interval, pharmacokinetics (PK), and immunogenicity following the fractionated GO dosing regimen have not been previously assessed. This phase IV study was designed to obt...

Descripción completa

Detalles Bibliográficos
Autores principales: Montesinos, Pau, Kota, Vamsi, Brandwein, Joseph, Bousset, Pierre, Benner, Rebecca J., Vandendries, Erik, Chen, Ying, McMullin, Mary Frances
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996548/
https://www.ncbi.nlm.nih.gov/pubmed/36892676
http://dx.doi.org/10.1007/s00280-023-04516-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996548/
https://www.ncbi.nlm.nih.gov/pubmed/36892676
http://dx.doi.org/10.1007/s00280-023-04516-9

Ejemplares similares